K4 Score test – pro
Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm named K4 score Test was subjected to ameta-nalysis by Zappala et al. The pooled estimate of 4Kscore Test discrimination (AUC) for high-grade PCa is >0.80, andwas consistent across multiple US and European clinical validation studies.
The NCCN The panel consensus is that the test can be considered for patients prior to biopsy and for those with prior negative biopsy who are thought to be at higher risk for clinically significant prostate cancer. It is important for patients and their urologists to understand, however, that no optimal cutoff threshold has been established for the 4Kscore. If a 4Kscore test is performed, patients and their urologists should discuss the results to decide whether to proceed with a biopsy.
Borque-Fernando Á, Rubio-Briones J, Esteban LM, et al. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2019; 22(1):84-90.
Bryant RJ, Sjoberg DD, Vickers AJ, et.al. Predicting high-grade cancer at ten-core prostate biopsy using four
kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015; 11:107(7).
Zappala SM, Scardino PT, Okrongly D, Linder V, Dong Y. Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. Rev Urol. 2017;19(3):149-155.
Carlsson S, Maschino A, Schröder F, et.al. Predictive value of four kallikrein markers for pathologically insignificant
compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European
Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol. 2013; 64(5):693-699.
NCCN Early Detection of Prostate Cane MS-24, 2024